158 related articles for article (PubMed ID: 32842710)
1. Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia.
Geissler K; Jäger E; Barna A; Gurbisz M; Graf T; Graf E; Nösslinger T; Pfeilstöcker M; Machherndl-Spandl S; Stauder R; Zebisch A; Sill H; Öhler L; Kusec R; Hörmann G; Valent P
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842710
[TBL] [Abstract][Full Text] [Related]
2. Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 Patients.
Geissler K; Jäger E; Barna A; Gurbisz M; Graf T; Graf E; Nösslinger T; Pfeilstöcker M; Tüchler H; Sliwa T; Keil F; Geissler C; Heibl S; Thaler J; Machherndl-Spandl S; Zach O; Weltermann A; Bettelheim P; Stauder R; Zebisch A; Sill H; Schwarzinger I; Schneeweiss B; Öhler L; Ulsperger E; Kusec R; Germing U; Sperr WR; Knöbl P; Jäger U; Hörmann G; Valent P
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32344757
[TBL] [Abstract][Full Text] [Related]
3. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
4. High spontaneous colony growth in chronic myelomonocytic leukemia correlates with increased disease activity and is a novel prognostic factor for predicting short survival.
Sagaster V; Ohler L; Berer A; Kabrna E; Ofner P; Lechner K; Geissler K
Ann Hematol; 2004 Jan; 83(1):9-13. PubMed ID: 13680175
[TBL] [Abstract][Full Text] [Related]
5. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
Kohlmann A; Grossmann V; Klein HU; Schindela S; Weiss T; Kazak B; Dicker F; Schnittger S; Dugas M; Kern W; Haferlach C; Haferlach T
J Clin Oncol; 2010 Aug; 28(24):3858-65. PubMed ID: 20644105
[TBL] [Abstract][Full Text] [Related]
6. Mutations in chronic myelomonocytic leukemia and their prognostic relevance.
Jian J; Qiao Y; Li Y; Guo Y; Ma H; Liu B
Clin Transl Oncol; 2021 Sep; 23(9):1731-1742. PubMed ID: 33861431
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo effects of JAK2 inhibition in chronic myelomonocytic leukemia.
Geissler K; Jäger E; Barna A; Sliwa T; Knöbl P; Schwarzinger I; Gisslinger H; Valent P
Eur J Haematol; 2016 Dec; 97(6):562-567. PubMed ID: 27157043
[TBL] [Abstract][Full Text] [Related]
8. CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia.
Watanabe J; Sato K; Osawa Y; Horiuchi T; Kato S; Hikota-Saga R; Maekawa T; Yamamura T; Kobayashi A; Kobayashi S; Kimura F
Int J Hematol; 2018 Jul; 108(1):47-57. PubMed ID: 29600428
[TBL] [Abstract][Full Text] [Related]
9. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.
Jankowska AM; Makishima H; Tiu RV; Szpurka H; Huang Y; Traina F; Visconte V; Sugimoto Y; Prince C; O'Keefe C; Hsi ED; List A; Sekeres MA; Rao A; McDevitt MA; Maciejewski JP
Blood; 2011 Oct; 118(14):3932-41. PubMed ID: 21828135
[TBL] [Abstract][Full Text] [Related]
10. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
You X; Liu F; Binder M; Vedder A; Lasho T; Wen Z; Gao X; Flietner E; Rajagopalan A; Zhou Y; Finke C; Mangaonkar A; Liao R; Kong G; Ranheim EA; Droin N; Hunter AM; Nikolaev S; Balasis M; Abdel-Wahab O; Levine RL; Will B; Nadiminti KVG; Yang D; Geissler K; Solary E; Xu W; Padron E; Patnaik MM; Zhang J
Blood; 2022 Feb; 139(7):1066-1079. PubMed ID: 34699595
[TBL] [Abstract][Full Text] [Related]
11. Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance.
Han W; Zhou F; Wang Z; Hua H; Qin W; Jia Z; Cai X; Chen M; Liu J; Chao H; Lu X
Int J Hematol; 2022 Jan; 115(1):21-32. PubMed ID: 34449040
[TBL] [Abstract][Full Text] [Related]
12. Deficiency of β Common Receptor Moderately Attenuates the Progression of Myeloproliferative Neoplasm in NrasG12D/+ Mice.
Zhang J; Ranheim EA; Du J; Liu Y; Wang J; Kong G; Zhang J
J Biol Chem; 2015 Jul; 290(31):19093-103. PubMed ID: 26082490
[TBL] [Abstract][Full Text] [Related]
13. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
[TBL] [Abstract][Full Text] [Related]
14. Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival.
Geissler K; Jäger E; Barna A; Graf T; Graf E; Öhler L; Hoermann G; Valent P
Eur J Haematol; 2021 May; 106(5):627-633. PubMed ID: 33432601
[TBL] [Abstract][Full Text] [Related]
15. Age-related mutations and chronic myelomonocytic leukemia.
Mason CC; Khorashad JS; Tantravahi SK; Kelley TW; Zabriskie MS; Yan D; Pomicter AD; Reynolds KR; Eiring AM; Kronenberg Z; Sherman RL; Tyner JW; Dalley BK; Dao KH; Yandell M; Druker BJ; Gotlib J; O'Hare T; Deininger MW
Leukemia; 2016 Apr; 30(4):906-13. PubMed ID: 26648538
[TBL] [Abstract][Full Text] [Related]
16. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis.
Carr RM; Vorobyev D; Lasho T; Marks DL; Tolosa EJ; Vedder A; Almada LL; Yurcheko A; Padioleau I; Alver B; Coltro G; Binder M; Safgren SL; Horn I; You X; Solary E; Balasis ME; Berger K; Hiebert J; Witzig T; Buradkar A; Graf T; Valent P; Mangaonkar AA; Robertson KD; Howard MT; Kaufmann SH; Pin C; Fernandez-Zapico ME; Geissler K; Droin N; Padron E; Zhang J; Nikolaev S; Patnaik MM
Nat Commun; 2021 May; 12(1):2901. PubMed ID: 34006870
[TBL] [Abstract][Full Text] [Related]
17. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.
Frankel AE; Lilly M; Kreitman R; Hogge D; Beran M; Freedman MH; Emanuel PD; McLain C; Hall P; Tagge E; Berger M; Eaves C
Blood; 1998 Dec; 92(11):4279-86. PubMed ID: 9834234
[TBL] [Abstract][Full Text] [Related]
18. Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia.
Kloos A; Mintzas K; Winckler L; Gabdoulline R; Alwie Y; Jyotsana N; Kattre N; Schottmann R; Scherr M; Gupta C; Adams FF; Schwarzer A; Heckl D; Schambach A; Imren S; Humphries RK; Ganser A; Thol F; Heuser M
Leukemia; 2020 Nov; 34(11):2951-2963. PubMed ID: 32576961
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells.
Geissler K; Ohler L; Födinger M; Virgolini I; Leimer M; Kabrna E; Kollars M; Skoupy S; Bohle B; Rogy M; Lechner K
J Exp Med; 1996 Oct; 184(4):1377-84. PubMed ID: 8879210
[TBL] [Abstract][Full Text] [Related]
20. Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples.
Bernard V; Gebauer N; Dinh T; Stegemann J; Feller AC; Merz H
Int J Clin Exp Pathol; 2014; 7(4):1667-76. PubMed ID: 24817963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
